Document Detail

Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.
MedLine Citation:
PMID:  17351377     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Visceral fat obesity plays an essential role in the clustering of atherosclerotic multiple risk factors in the metabolic syndrome. Telmisartan, an angiotensin II type 1 receptor blocker, has partial agonistic properties for peroxisome proliferator-activated receptor gamma, which is a key regulator of adipocyte differentiation and function.
METHODS: This study aimed to clarify the impact of telmisartan on fat distribution and insulin sensitivity in the metabolic syndrome. In this open-label, prospective, randomized study, patients with the metabolic syndrome (waist circumference: men >or= 85 cm, women >or= 90 cm) were treated either with amlodipine (n = 26) or with telmisartan (n = 27) for 24 weeks, and fat distribution and insulin sensitivity were determined.
RESULTS: Systolic and diastolic blood pressure were decreased in both groups to a comparable level. However, insulin and glucose levels during an oral 75 g glucose loading were decreased only in the telmisartan group. The visceral fat area, determined by abdominal computed tomography scan, was reduced in the telmisartan group after 24 weeks' treatment, but the subcutaneous fat area did not change in either group.
CONCLUSION: The results imply that telmisartan could treat both the hemodynamic and metabolic aberrations seen in patients with the metabolic syndrome, improving insulin resistance and glucose intolerance at least partly through visceral fat remodeling.
Michio Shimabukuro; Hideaki Tanaka; Takeshi Shimabukuro
Related Documents :
20219977 - The positive effects of growth hormone-releasing peptide-6 on weight gain and fat mass ...
2647557 - Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resi...
17381487 - Interleukin-6, tumour necrosis factor-alpha and insulin relationships to body compositi...
25271207 - Exploring the potential of the sglt2 inhibitor dapagliflozin in type 1 diabetes: a rand...
19911877 - Challenges and advances in nanoparticle-based oral insulin delivery.
19420817 - Familial graves' disease associated with type 1 diabetes.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of hypertension     Volume:  25     ISSN:  0263-6352     ISO Abbreviation:  J. Hypertens.     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-03-12     Completed Date:  2007-08-07     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  841-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adipose Tissue, White / drug effects*
Amlodipine / therapeutic use
Analysis of Variance
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Aorta / drug effects,  physiopathology
Benzimidazoles / therapeutic use*
Benzoates / therapeutic use*
Biological Markers / blood
Blood Glucose / drug effects,  metabolism
Blood Pressure / drug effects
Body Fat Distribution
Calcium Channel Blockers / therapeutic use
Glucose Tolerance Test
Hypertension / blood,  drug therapy,  physiopathology
Insulin / blood
Insulin Resistance
Intra-Abdominal Fat / drug effects
Metabolic Syndrome X / blood,  drug therapy*,  physiopathology
Middle Aged
Prospective Studies
Research Design
Tomography, X-Ray Computed
Treatment Outcome
Vascular Resistance / drug effects
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Benzoates; 0/Biological Markers; 0/Blood Glucose; 0/Calcium Channel Blockers; 0/Insulin; 1J444QC288/Amlodipine; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic s...
Next Document:  Babies, pre-eclamptic mothers and grandparents: a three-generation phenotyping study.